Phil Rose appointed Chief Commercial Officer

Home » Company News » Phil Rose appointed Chief Commercial Officer
Hexima announces the appointment of Phillip Rose as Chief Commercial Officer, based in the U.S. Phillip Rose reports to Michael Aldridge, Managing Director & CEO.

Mr. Rose has over 30 years of leadership experience in the pharmaceutical industry, including President and CEO of the dermatology focused Obagi Medical Products, Vice President and General Manager of North America for Valeant (now Bausch Healthcare Companies) as well as Vice President Hospital Sales at Glaxo, Inc. (now GSK). In addition, Phil is a licenced and practicing Pharmacist.

Mr. Rose has served as a commercial consultant to the pharmaceutical industry and prior clients include Alza Corporation (now J&J), Reliant Pharmaceuticals (now GSK), Peplin, Inc. the developer of Picato (now LEO), and Hexima Limited since 2020.

Mr Rose will be a senior U.S.-based Hexima representative and will lead the implementation of Hexima’s commercial strategy and product development program.

Michael Aldridge, Managing Director & CEO said, “Phil has been an extraordinary asset to Hexima over the last two years as he has helped develop our US commercial strategy. He was particularly instrumental in the conceptualisation and early development of our CompliancePak and associated mobile application as well as engagement with the US dermatology and podiatry medical community.

He has also been hugely valuable in evaluating and isolating potentials for a second pipeline product candidate at Hexima.

“In view of the pending announcement of the results of our phase IIb clinical trial in Q2 2022, we continue to build out our US market presence and related preparations for our phase III program. I am very pleased to have Phil accept this critically important role.” He continued.

Commenting on his appointment, Phil Rose said “I could not be more excited to be formally joining this impressive Hexima team that is guiding pezadeftide through development toward commercialization. Onychomycosis is a high potential; unsatisfied market and I believe we have a real opportunity to improve the quality of care and treatment outcomes for millions of patients.”